Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Atezolizumab in mCRPC
NCT04272645Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Progression free survival at 6 months and Incidence of dose limiting toxicities at 21 days. Planned start Oct 2020; status: withdrawn.
02
Drugs
abemaciclibatezolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04272645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272645.